GSK-3β is highly expressed in the CNS and its activity is increased in the brain and plasma of AD patients.19–24 Abundant evidence suggests that the inhibition of GSK3β improves both synaptic and cognitive function in AD mouse model studies25–29 and useful therapy for a large of neurological diseases or disorders. Here, GSK3B is linked to nervous system disorder.